Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide

Rheumatology

Volumn 50, Issue 12, 2011, Pages 2270-2277

  van den Berg, Rosaline ^a   Stanislawska biernat, Ewa ^b   van der Heijde, Désirée M F M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Ankylosing spondylitis; Anti TNF therapy; ASAS; Recommendations

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTICLE; AUSTRALIA; BELGIUM; CANADA; COLOMBIA; CZECH REPUBLIC; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; FINLAND; FRANCE; GERMANY; GREECE; HONG KONG; HUMAN; HUNGARY; ITALY; KOREA; MEXICO; NETHERLANDS; NORWAY; PATIENT SELECTION; POLAND; PORTUGAL; PRIORITY JOURNAL; SACROILIITIS; SLOVAKIA; SPAIN; SWEDEN; SWITZERLAND; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UNITED KINGDOM;

ASIA; CANADA; COLOMBIA; CONSENSUS; EUROPE; HUMANS; MEXICO; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82355169062     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker270     Document Type: Article

References (20)

1. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
2. van der Heijde D, Landewe R, Baraliakos X et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
3. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
4. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
5. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
6. Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
7. Henderson C, Davis JC. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:211-8.
8. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
9. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
10. Davis JC Jr, van der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
11. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
12. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
13. Inman RD, Davis JC, van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-12.
14. Baraliakos X, Listing J, Fritz C et al. Persistent clinical efficacy and safety of anti-TNF alpha therapy with infliximab in patients with ankylosing spondylitis over 8 years. Ann Rheum Dis 2009;68(Suppl. 3):634.
15. Braun J, Davis J, Dougados M, Sieper J, van der Linden SM, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
16. van der Linden SM, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
17. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edn. Boston, MA: Little, Brown & Co, 1994.
18. Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2007;21:699-712.
19. Emery P, Van Vollenhoven R, Ostergaard M et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis 2009;68:456-9.
20. Spoorenberg A, van der Heijde D, de Klerk E et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatology 1999; 26:980-4.